Miss Sophie King

2026

• Knapper, S. et al. 2026. Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial. Blood (10.1182/blood.2025032681)
• Sheppard, R. et al. 2026. Decision on optimal combinatorial therapies in immune-mediated inflammatory diseases using systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis. Rheumatology Advances in Practice 10 (2) rkag036. (10.1093/rap/rkag036)
• Knapper, S. et al. 2026. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood 147 (10), pp.1048-1057. (10.1182/blood.2025031006)

2023

• Knapper, S. et al., 2023. S131: a randomised assessment of the sequential addition of the kinase inhibitor Quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial [Abstract]. HemaSphere 7 , pp.69-70. e0819670. (10.1097/01.hs9.0000967436.08196.70)

2022

• Freeman, S. D. et al., 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140 (S1), pp.532-533. (10.1182/blood-2022-162245)